FORWARD I: A Phase III Study of Mirvetuximab Soravtansine Versus Chemotherapy in Platinum-Resistant Ovarian Cancer

Kathleen N Moore1 Department of Obstetrics & Gynecology, Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USACorrespondence[email protected]

Ignace Vergote2 Gynaecological Oncology, Leuven Cancer Institute, Leuven3000, Belgium

Ana Oaknin3 Medical Oncology Department, Vall D’Hebron Institute of Oncology (VHIO), Barcelona08035, Spain

Nicoletta Colombo4 Gynecologic Oncology, The European Institute of Oncology, Milan20141, Italy

Susana Banerjee5 Gynaecology Unit, Royal Marsden Hospital, London, SW3 6JJ, UK

Amit Oza6 Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, TorontoM5G 2M9, Canada

Patricia Pautier7 Department of Adult Medicine, Gustave Roussy Cancer Campus, Villejuif94800, France

Karim Malek8 Clinical Development, ImmunoGen, Inc., Waltham, MA 02451, USA

Michael J Birrer9 Division of Hematology–Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL 35294, USA

show all

FORWARD I: A Phase III Study of Mirvetuximab Soravtansine Versus Chemotherapy in Platinum-Resistant Ovarian Cancer

Infographic

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

FORWARD I: A Phase III Study of Mirvetuximab Soravtansine Versus Chemotherapy in Platinum-Resistant Ovarian Cancer

Infographic

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date